Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?
about
Overexpressed oncogenic tumor-self antigensGenetic architecture of colorectal cancer.Epigenetic silencing of miR-145-5p contributes to brain metastasisDecreased TPD52 expression is associated with poor prognosis in primary hepatocellular carcinomaDropping in on the lipid droplet- tumor protein D52 (TPD52) as a new regulator and resident protein.miR-139-5p regulates proliferation, apoptosis, and cell cycle of uterine leiomyoma cells by targeting TPD52.In-depth LC-MS/MS analysis of the chicken ovarian cancer proteome reveals conserved and novel differentially regulated proteins in humansSuppression of PC-1/PrLZ sensitizes prostate cancer cells to ionizing radiation by attenuating DNA damage repair and inducing autophagic cell death.Dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p) coordinately targeted MTDH in lung squamous cell carcinoma.Global methylation profiling to identify epigenetic signature of gallbladder cancer and gallstone disease.Tumor-suppressive microRNA-34a inhibits breast cancer cell migration and invasion via targeting oncogenic TPD52.Tumor Proteins D52 and D54 Have Opposite Effects on the Terminal Differentiation of ChondrocytesPlatform-independent gene expression signature differentiates sessile serrated adenomas/polyps and hyperplastic polyps of the colon.Tumor protein D52 (isoform 3) contributes to prostate cancer cell growth via targeting nuclear factor-κB transactivation in LNCaP cells.Androgen-dependent alternative mRNA isoform expression in prostate cancer cellsLong non‑coding RNA ferritin heavy polypeptide 1 pseudogene 3 controls glioma cell proliferation and apoptosis via regulation of the microRNA‑224‑5p/tumor protein D52 axis
P2860
Q35886756-E2DDE618-F244-42B9-A483-D43E3F518200Q36053127-3CBAFB27-0509-422F-A48F-242831324088Q36546293-5E9B799A-7BFB-4331-86F8-047022099438Q36905913-D9B34226-110A-4814-8EE1-9A87276393CCQ37238021-70E6274D-DA6B-4733-8DF1-438A3A897E16Q37344530-0F471D8F-5651-41D1-8A98-61656CE3112BQ37607036-6AF2841B-89D4-4BCD-AE6B-23719488E8C0Q37641774-BD453377-7B8A-4B92-9346-35FB41969140Q37687781-985ADDFA-C88B-4D67-8D4C-27FCCCFEDEF6Q39395261-DFC7C300-926A-4E0E-957D-A177BA418648Q40200300-4B0C0094-2EDD-4A60-A875-300CDD5747ADQ41180083-A0863F75-9DEC-44B8-9E02-DFD1AAD9CA8BQ47111568-BCF2F1FE-582C-4B10-823D-FE1054002CAEQ51022990-85E36458-EAD1-48A6-BBB7-D80D7D7DBEBCQ57135534-B8C42710-5E05-4583-8EEB-295A8402FA83Q57157341-C973883D-32ED-4B3B-8A13-C77BCF99368F
P2860
Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?
@en
type
label
Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?
@en
prefLabel
Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?
@en
P2860
P1433
P1476
Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?
@en
P2093
Robert K Bright
Yuyan Chen
P2860
P2888
P304
P356
10.1007/S13277-014-2006-X
P577
2014-05-06T00:00:00Z
P5875
P6179
1051209439